Orgenesis Inc. (ORGS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ORGS POWR Grades
- Growth is the dimension where ORGS ranks best; there it ranks ahead of 99.26% of US stocks.
- The strongest trend for ORGS is in Value, which has been heading down over the past 31 weeks.
- ORGS's current lowest rank is in the Quality metric (where it is better than 17.58% of US stocks).
ORGS Stock Summary
- With a price/earnings ratio of 1.68, Orgenesis Inc P/E ratio is greater than that of about only 0.67% of stocks in our set with positive earnings.
- Of note is the ratio of Orgenesis Inc's sales and general administrative expense to its total operating expenses; only 6.24% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for Orgenesis Inc comes in at -45.52%, a number that bests just 7.73% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ORGS, based on their financial statements, market capitalization, and price volatility, are ACRS, APTX, CUE, FGEN, and ARLO.
- ORGS's SEC filings can be seen here. And to visit Orgenesis Inc's official web site, go to www.orgenesis.com.
ORGS Price Target
For more insight on analysts targets of ORGS, see our ORGS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ORGS Stock Price Chart Interactive Chart >
ORGS Price/Volume Stats
| Current price | $5.47 | 52-week high | $8.30 |
| Prev. close | $5.57 | 52-week low | $4.14 |
| Day low | $5.29 | Volume | 105,500 |
| Day high | $5.63 | Avg. volume | 339,506 |
| 50-day MA | $5.03 | Dividend yield | N/A |
| 200-day MA | $5.41 | Market Cap | 133.91M |
Orgenesis Inc. (ORGS) Company Bio
Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. The company was founded in 2008 and is based in Germantown, Maryland.
Latest ORGS News From Around the Web
Below are the latest news stories about Orgenesis Inc that investors may wish to consider to help them evaluate ORGS as an investment opportunity.
Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repairInvestigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (“SVF”) injections after rotator cuff surgeryGERMANTOWN, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, announces that enrollment has commenced for a clinical trial using the Tissue Genesis Icellator® at the Hospital for Special |
Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2ndGERMANTOWN, Md., June 01, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be presenting at the Summer Solstice Conference, hosted by The MicroCap Rodeo, being held virtually on June 1st – June 4th, 2021. Vered Caplan, CEO of Orgenesis is scheduled to present on Wednesday, June 2nd, 2021 at 2:30 PM, Eastern Time and will participate in one-on-one meetings with investors and analysts throughout the conference. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2134/41525. To receive additional information about the conference, request an invitation, or to schedule a one-on-one me... |
Orgenesis: A Mispriced Visionary In Cell And Gene Therapy ManufacturingEditor's note: Seeking Alpha is proud to welcome Kelvin Seetoh as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click here to find out more » Photo by metamorworks/iStock via... |
Orgenesis Schedules First Quarter 2021 Business Update Conference CallGERMANTOWN, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a conference call at 8:30 AM Eastern Time on Friday, May 7, 2021 to discuss the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or for international callers +1 973-528-0011 and using entry code 173027. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2585/41278 or on the Company’s Investor Events section of the website here. A webcast replay will be available on the Company’s Investor Events section of the website... |
Orgenesis Enters into Collaboration Agreement with the Bambino Gesù Children's Hospital in Rome to Establish Point of Care Cell and Gene Therapy CenterGERMANTOWN, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, announces that it has entered a collaboration with the Bambino Gesù Children's Hospital in Rome to establish a Point of Care Cell Therapy center at the Hospital. Process work will be focused on supporting clinical trials related to therapies developed by both the Hospital and Orgenesis, joint research, development of new approaches, and validation activities for advanced cell and gene therapies. “At the Bambino Gesù Children's Hospital, we are developing a number of cutting-edge therapies. Orgenesis’ new point-of-care center is being implemented to optimize promising therapies to potent... |
ORGS Price Returns
| 1-mo | 8.10% |
| 3-mo | -30.67% |
| 6-mo | 14.92% |
| 1-year | -17.37% |
| 3-year | -40.67% |
| 5-year | 13.99% |
| YTD | 21.56% |
| 2020 | -3.43% |
| 2019 | -0.43% |
| 2018 | -18.68% |
| 2017 | 54.65% |
| 2016 | -3.09% |
Loading social stream, please wait...